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Polo-like kinase 1 (Plk1) appears to be an attractive target for anticancer therapy. In this issue of Chemistry &
Biology, Reindl et al. (2008) describe the identification of a small molecule called Poloxin that appears to
interfere with the function of the polo-box domain (PBD) of Plk1.The polo-like kinases (Plks) belong to
a conserved subfamily of Ser/Thr protein
kinases that play critical roles in cellular
proliferation from yeast to mammals
(Barr et al., 2004). Plks are characterized
by the presence of a highly conserved
polo-box domain (PBD) in the C-terminal
noncatalytic region. In mammalian cells,
three closely related (Plk1, Plk2/Snk, and
Plk3/Prk) and one distantly related (Plk4/
Sak) kinase have been identified with ap-
parently distinct expression patterns and
physiological functions (because of a dis-
similar PBD-binding module, Plk4 will not
be further discussed hereafter). Among
these, Plk1 has been the focus of exten-
sive studies because of its strong associ-
ation with oncogenic transformation of
human cells. Overexpression of Plk1 is
observed in a broad spectrum of human
cancers and appears to be sufficient to
override cellular checkpoints and induce
genetic instability, thus promoting tumor-
igenesis. Conversely, interference with
Plk1 function results in apoptotic cell
death in various tumor cells but not in nor-
mal cells, and induces tumor regression in
mouse xenograft models (Strebhardt and
Ullrich, 2006). Thus, Plk1 appears to be an
attractive target for therapeutic interven-
tion against human cancers. In contrast
to Plk1, the two related kinases, Plk2
and Plk3, appear to play roles in check-
point-mediated cell cycle arrest to ensure
genetic stability and prevent oncogenic
transformation, suggesting that specific
inhibition of Plk1 is likely important for
anti-Plk1 cancer therapy.
Over the years, efforts have been made
to generate anti-Plk1 inhibitors, yielding
several compounds that appear to com-
petitively inhibit the kinase activity or the
substrate recognition of Plk1 (Strebhardt
and Ullrich, 2006). However, because
all Plks have structurally similar kinasedomains, these compounds also signifi-
cantly inhibit Plk2 and Plk3. A growing
bodyof evidence suggests that thenonca-
talytic PBD plays a pivotal role for mitotic
functions of Plk1 by targeting the catalytic
activity to the centrosomes, kinetochores,
and midbody (Barr et al., 2004; Lee et al.,
1998). Later studies show that the PBD is
composed of two structurally related PB1
(residues 411–489 in Plk1) and PB2 (resi-
dues 511–592) motifs that form a phos-
pho-Ser/Thr-binding module critical for
protein-protein interaction (Cheng et al.,
2003; Elia et al., 2003). Since Plks carry
out distinct cellular functions, the nature
of the PBD-dependent interaction for indi-
vidual Plks is likely different from each
other, thus leading to the speculation that
specific inhibition of the PBD of Plk1 will
likely constitute an alternative strategy for
anti-Plk1 cancer therapy.
In an effort to isolate PBD inhibitors,
Reindl et al. (2008) developed a novel
high-throughput fluorescence polarization
assay designed to identify compounds
that disrupt the interaction between Plk1
PBDandafluorophore-labeledPBD-bind-
ing peptide. This approach led to the iden-
tification of a thymoquinone derivative
named Poloxin that inhibits the PBD inter-
action with an apparent IC50 of 4.8 mM.
Poloxin exhibited a loose Plk1 PBD speci-
ficity with 4–10 times higher IC50 values for
Plk2 and Plk3, and did not significantly in-
hibit other types of phosphopeptide-bind-
ing domains such as FHA, WW, and SH2
domains. In cellular assays, Poloxin ap-
peared to inhibit Plk1PBD function, induc-
ing Plk1 delocalization from specific sub-
cellular structures and ultimately leading
to a mitotic arrest and apoptotic cell death
(Figure 1A; see Reindl et al. in this issue for
details). These findings demonstrate that
inhibition of the PBD is sufficient to inter-
fere with the mitotic functions of Plk1 andChemistry & Biology 15, May 200further provide the proof-of-principle that
generation of the PBD inhibitors with po-
tency and selectivity is plausible. Whether
Poloxin will display antitumorigenic activ-
ity in animal tumor models and whether
its pharmacokinetic and physicochemical
propertieswill be suitable for clinical appli-
cation remain to be determined.
Apart from the future in vivo studies on
the efficacy of Poloxin, further investiga-
tion on the mode of its action at the
molecular level will be an important task.
Whether Poloxin binds to Plk1 as the
primary cellular target and how Poloxin in-
hibits the function of PBDare not known at
present. Notably, Poloxin does not bear
a negatively charged group functionally
equivalent to the phosphate anchor of
PBD-binding phosphopeptides, suggest-
ing that it does not directly bind to the
phospho-Ser/Thr- docking module of the
PBD. Rather, Poloxin is an iminoquinone
which, like simple a,b-unsaturated ke-
tones, may undergo Michael additions
with biological thiols, such as glutathione,
free Cys, and Cys residues in cellular
proteins. Given that Plk1 PBD possesses
at least five surface-exposed Cys resi-
dues, according to the available PBD
structure, it is tempting to speculate that
Poloxin may covalently bind to these sur-
face Cys residues in a way that disrupts
the function of PBD. In support of this
view, it is well established that the struc-
turally related acetaminophen metabolite,
N-acetyl-p-benzoquinone imine (NAPQI),
is highly reactive and readily generates
thiol-NAPQI conjugates through a nucleo-
philic sulfhydryl-bearing moieties (Chen
et al., 2008; Figure 1B). Other established
biologically reactive iminoquinones in-
clude the reactive metabolites of the anti-
biotic trimethoprim (Lai et al., 1999) and
3-(N-phenylamino)propane-1,2-diol, the
moiety believed to be responsible for8 ª2008 Elsevier Ltd All rights reserved 415
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(Martı´nez-Cabot et al., 2005).
These findings raise the ques-
tion of whether the iminoqui-
none moiety in Poloxin can
cause an unacceptable level
of cytotoxicity in vivo. It is im-
portant to note, however, that
Poloxin shows a high level of
selectivity against Plk1 among
a range of phosphopeptide-
binding proteins tested, sug-
gesting that the 2-methylben-
zoate group tethered to the
reactive thymoquinonemoiety
of Poloxin may play a pivotal
role inbringingPoloxin inprox-
imity to the PBD of Plk1. Since
disruption of the PBD function
might require a specific alter-
ation of the PBD structure, un-
derstanding theprecisenature
of Poloxin binding to the PBD
will be critical for providing
new insights into the design
of additional anti-Plk1 PBD
agents. Identification of the
site(s) of potential Michael ad-
dition and determination of
crystal structures of the Plk1
PBD in complex with Poloxin
will likely broaden our under-
standing of how Poloxin in-
hibits the function of the PBD.
As Plk1 expression is lim-
ited to mitotically dividing
cells and tissues, anti-Plk1
agents clearly provide
a significant advantage over
the broad antimicrotubule
agents, such as the taxanes
and vinca alkaloids, that
have been used successfully
to treat diverse human can-
cers. Although many inhibi-
tors targeting the ATP-bind-
ing site of catalytic domain appear to
display reasonable selectivity, the struc-
tural similarities among various kinases
present major challenges in precluding
nonspecific inhibition of other cellular ki-
nases. Additionally, kinase inhibitors fre-
quently lead to the development of drug
resistance as a result of accumulating
mutations in the ATP binding site. There-
fore, targeting an essential noncatalytic
domain with diminished likelihood of non-
specificity would serve as an alternative
approach. In this regard, isolation and fur-
ther development of PBD-targeting small
molecule inhibitors that can be used ei-
ther alone or in combination with Plk1 ki-
nase domain inhibitors will be vital to im-
prove the efficacy of Plk1 inhibition while
reducing the risk of yielding
molecular resistance.
Better understanding of the
exact nature of the PBD-bind-
ing and elements required
for achieving the specificity
between PBD and its binding
targets will be central for the
development of anti-Plk1 ther-
apeutic agents. Isolation of
novel PBD-binding agents
and further investigation of
Poloxin or Poloxin-like small
molecule inhibitors with both
high affinity and high specific-
ity for thePlk1PBDwillbeadif-
ficult but worthwhile challenge
for the generation of a new
class of anti-Plk1 therapeutic
agents. Nevertheless, the
presence of an iminoquinone
moiety within the anti-Plk1
pharmacophore may impose
a concern in the development
of compounds that have high
efficacyalongwith acceptable
toxicity in vivo.
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Figure 1. PBD-Dependent Subcellular Localization of Plk1 and
Proposed Mechanism of Covalent Conjugation between Poloxin
and Sulphhydryl-Containing Targets
(A) Plk1 localizes to the specific subcellular structures through the interaction
between the PBD and its phosphorylated binding targets at specific subcellu-
lar locations. Poloxin binds to the PBD in a manner that is not clearly under-
stood at present and interferes with the PBD-dependent subcellular localiza-
tion. This event ultimately leads to a mitotic arrest and apoptotic cell death.
KD and PBD, kinase domain and polo-box domain, respectively, of Plk1.
(B) Positions of established or putative (in the case of Poloxin) nucleophilic at-
tack by biological thiol groups, indicated by arrows, for [1], Poloxin; [2], tri-
methoprim iminoquinone methide metabolic intermediate (Lai et al., 1999);
[3], NAPQI, the reactive metabolite of acetaminophen (Chen et al., 2008); [4],
the iminoquinone reactive metabolite of 3-(N-phenylamino)propane-1,2-diol,
associated with Spanish toxic oil syndrome (Martı´nez-Cabot et al., 2005).416 Chemistry & Biology 15, May 2008 ª2008 Elsevier Ltd All rights reserved
